Citigroup Inc Dexcom Inc Put Options Transaction History

Citigroup Inc

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 12, 2024	BUY	$64.0 - $116.06 $11.8 Million - $21.4 Million	184,000 Added 149.59%	307,000 $20.6 Million
Q2 2024 Aug 12, 2024	BUY	$110.31 - $140.45 $13.6 Million - $17.3 Million	123,000 New	123,000 $13.9 Million
Q2 2023 Aug 10, 2023	SELL	$112.47 - $130.98 $16.9 Million - $19.6 Million	-150,000 Reduced 54.55%	125,000 $16.1 Million
Q1 2023 May 11, 2023	BUY	$104.0 - $122.92 $312,000 - $368,760	3,000 Added 1.1%	275,000 $31.9 Million
Q4 2022 Feb 09, 2023	SELL	$84.98 - $122.67 $10.6 Million - $15.3 Million	-125,000 Reduced 31.49%	272,000 $30.8 Million
Q3 2022 Nov 10, 2022	BUY	$76.35 - $94.18 $26.5 Million - $32.7 Million	347,000 Added 694.0%	397,000 $32 Million
Q2 2022 Aug 10, 2022	BUY	$67.99 - $132.89 $2.72 Million - $5.32 Million	40,000 Added 400.0%	50,000 $3.73 Million
Q4 2021 Feb 10, 2022	BUY	$129.87 - $162.82 $1.3 Million - $1.63 Million	10,000 New	10,000 $5.37 Million

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.